Phase II Lap/Epi: Phase II evaluation of the combination of epirubicin and lapatinib in Her-2 positive, Topoisomerase II alpha positive, metastatic breast cancer.
Phase of Trial: Phase II
Latest Information Update: 11 Sep 2014
At a glance
- Drugs Epirubicin (Primary) ; Lapatinib (Primary)
- Indications Advanced breast cancer
- Focus Biomarker; Therapeutic Use
- 14 Dec 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
- 22 Feb 2012 New trial record